H2Mab-139
H2Mab-139 (H2Mab-141;H2Mab-19) is an anti-HER2 monoclonal antibody. H2Mab-139 specifically binds to HER2 on various cancer cells. H2Mab-139 can detect HER2 overexpression in colorectal cancer via flow cytometry and immunohistochemical analysis. H2Mab-139 exhibits anti-tumor activity in mouse oral cancer and breast cancer xenografts. H2Mab-139 is applicable to research related to multiple cancers including colon cancer, oral cancer, and breast cancer.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
All EGFR Isoforms
More
Biological Activity
Description
Species Reactivity
Human
In Vitro
H2Mab-139 (10 μg/mL; 30 min at 4°C) specifically binds to HER2 on LN229/HER2 glioblastoma cells and the colorectal cancer cell lines Caco-2, HCT-116, HCT-15, HT-29, LS 174T, COLO 201, COLO 205, HCT-8, SW1116, and DLD-1 in flow cytometry assays[1].
H2Mab-139 (10 μg/mL) specifically detects HER2 protein with a molecular weight of approximately 200 kDa in LN229/HER2 glioblastoma cell lysates via Western blotting[1].
H2Mab-139 (10 μg/mL; 1 h at room temperature) specifically stains the cell membrane of HER2-positive human colon cancer tissue sections in immunohistochemical assays[1].
H2Mab-19 (6 ng/mL to 100 μg/mL) maintains high binding affinity for HER2 in HER2-expressing BT-474, HSC-2, and SAS cell lines, with Kd values of 2.3 × 10-8 M, 9.5 × 10-9 M, and 5.5 × 10-9 M, respectively[2].
H2Mab-19 (5 h at 37°C) exhibits high CDC activity against BT-474, HSC-2 and SAS cell lines, with cytotoxicity rates of 46%, 51% and 53%, respectively[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
H2Mab-19 (100 μg per dose; i.p.; on days 1, 6, and 14 after cell implantation) significantly reduces tumor development and tumor weight in HSC-2 oral cancer xenografts[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (female, 10 weeks old, purchased at 6 weeks old) BT-474 cells (1.33x108) [2]
-
Dosage:100 μg per dose
-
Administration:i.p.; on days 1, 7, and 14 after cell implantation
-
Result:Significantly reduced tumor development compared to controls on days 5, 7, 12, 15, and 18 post-implantation.
Significantly reduced tumor weights compared to control mice.
Showed no significant difference in total body weight compared to control mice.
-
Animal Model:BALB/c nude (female, 10 weeks old, purchased at 6 weeks old) HSC-2 or SAS cell (1.33x108)[2]
-
Dosage:100 μg per dose
-
Administration:i.p.; on days 1, 6, and 14 after cell implantation
-
Result:Significantly reduced tumor development compared to controls on days 6, 10, 14, 17, and 20 post-implantation.
Significantly reduced tumor weights compared to control mice.
Showed no significant difference in total body weight compared to control mice.\nSignificantly reduced tumor development compared to controls on days 14, 17, and 20 post-implantation.
Significantly reduced tumor weights compared to control mice.
Showed no significant difference in total body weight compared to control mice.
Gene ID
Accession
Target
ERBB2/HER2/CD340
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
ELISA, FACS, Functional assay
Chemical Information
-
SMILES
[H2Mab-139]
-
Synonyms
H2Mab-141, H2Mab-19
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Flow Cytometry
Flow cytometry (FC) is a technique for high-speed, step-by-step quantitative analysis and sorting of single cells or other biological particles in a suspension by detecting labeled fluorescent signals.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Protocol for Phospho-flow cytometry
Phospho-flow cytometry detects intracellular phosphorylated signaling proteins in single cells using phospho-specific antibodies after rapid fixation and permeabilization; the fluorescence intensity reflects phosphorylation state and therefore kinase-pathway activation, inhibition, or drug response in defined cell subsets. Unlike Western blot, phospho-flow preserves single-cell resolution and can measure signaling heterogeneity in cancer cells, primary immune cells, dissociated mouse tumors, macrophages, organoid-derived cells, and drug-screening samples when validated antibodies and fixation/permeabilization conditions are used.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Purity & Documentation
References
[1]. Kaneko MK, et al. Development of an Anti-HER2 Monoclonal Antibody H2Mab-139 Against Colon Cancer. Monoclon Antib Immunodiagn Immunother. 2018;37(1):59-62. [Content Brief]
[2]. Takei J, et al. H2Mab-19, an anti-human epidermal growth factor receptor 2 monoclonal antibody exerts antitumor activity in mouse oral cancer xenografts. Exp Ther Med. 2020;20(2):846-853. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
H2Mab-139 Related Classifications
HY-P991980 Related Classifications
Powered by Bioz